+1 more
TryptamineLSD, psilocybin, mescaline +1 moreLSD, psilocybin, mescaline, DMT show less
LAE-32
lysergic acid ethylamide
LAE-32 (lysergic acid ethylamide) is a semi-synthetic psychedelic of the lysergamide class. It is the direct structural predecessor of LSD, one ethyl group simpler and roughly 10–20 times less potent.[1] It activates serotonin receptors in the brain, producing the perceptual and cognitive shifts of classical psychedelics.[2]
LAE-32 (lysergic acid ethylamide) is a semi-synthetic psychedelic of the lysergamide class. It is the direct structural predecessor of LSD, differing by one ethyl group and roughly 10–20 times less potent.[1] LAE-32 is a presumed 5-HT₂A receptor agonist, producing its effects by disrupting serotonin-mediated sensory gating in the cortex.[2]
+1 more
TryptamineLSD, psilocybin, mescaline +1 moreLSD, psilocybin, mescaline, DMT show less
LAE-32 was synthesized by Albert Hofmann's team at Sandoz Laboratories in the 1950s during the same research programme that produced LSD. A small cluster of Italian clinical studies appeared between 1955 and 1959,[3][4][1][5] then all investigation stopped. It has never appeared on contemporary drug markets and remains an obscure historical footnote in lysergamide chemistry.
Subjective effects include geometric visual patterns, identity alteration, personal insight, motivation suppression, and physical sedation. The experience is dreamier and more sedating than LSD — closer in character to ergine (LSA) than to the bright analytical stimulation of its diethyl parent.[1] Anxiety, apathy, and bodily heaviness are characteristic undesired effects.
LAE-32 produces no physical dependence, and ergolines as a class show a very high physiological safety margin.[2] The primary danger is psychological — panic, transient psychosis, or lasting destabilization — amplified in predisposed individuals and by serotonin-elevating combinations such as MAOIs. The evidence base is exceptionally thin: all primary data come from 1950s Italian clinical reports, and no modern pharmacological study has been conducted.
History[edit]
History
Discovery
LAE-32 was synthesized at Sandoz Laboratories in Basel by Albert Hofmann's team as part of a systematic investigation of lysergic acid amide derivatives — the same programme that produced LSD. The name derives from the German Lysergsäure-Äthylamid, compound 32 in the Sandoz internal numbering system. The first clinical report appeared in 1955, when Tonini and Montanari described its psychological effects in human subjects.[3]
Clinical research
A small body of Italian-language literature followed over the next four years. Callieri and Ravetta documented psychopathological experiences during combined LAE-32 and LSD-25 administration.[4] Giberti and Gregoretti conducted the most informative study — a comparative investigation of LAE-32 versus LSD in neurotic patients.[1] Soriani and Favale examined the compound's interaction with chronic serotonin treatment in mice.[5]
Modern status
No further research has been published since 1959. LAE-32 has not appeared on contemporary research chemical markets and has no registered clinical trials. It remains a historical curiosity, overshadowed by LSD and by later lysergamides such as 1P-LSD, ALD-52, and ETH-LAD.
The compound has no street names and no cultural presence outside specialist pharmacological literature. Multiple secondary sources claim LAE-32 was tested within the CIA's Project MKULTRA programme, but this has not been confirmed from primary declassified documents.citation needed
Chemistry[edit]
Chemistry
LAE-32 belongs to the ergoline and lysergamide chemical classes — the same structural family as LSD and the natural compound ergine. Its molecular formula is C₁₈H₂₁N₃O. Structurally it sits between ergine (no alkyl groups on the amide nitrogen) and LSD (two ethyl groups) — the N-monoethyl midpoint of the series.[6]
The difference from LSD is a single ethyl group. Losing that group reduces how well the molecule fits the serotonin receptor, accounting for the 10–20-fold potency reduction.[7] N-monoalkyl lysergamides retain psychedelic activity despite the smaller structure,[8] but only the (6aR,9R) stereoisomer is pharmacologically active — the mirror-image form is inert at relevant doses.[9]
Pharmacology[edit]
Pharmacology
Mechanism of action
Psychedelic effects from LAE-32 arise from partial activation of serotonin receptors in the cortex. This drives increased glutamate release, disrupting the brain's normal sensory filtering and producing the perceptual changes characteristic of classical psychedelics.[2]
Like LSD, LAE-32 is expected to interact with dopamine and other monoamine systems.[10] The loss of one ethyl group reduces how tightly the molecule fits the serotonin receptor, explaining the 10–20-fold potency reduction.[7][1]
inferred All pharmacological designations for LAE-32 are structural inferences from the lysergamide class. No substance-specific binding or functional data exist.
Pharmacokinetics
No pharmacokinetic data have been published for LAE-32. LSD provides the closest reference: peak plasma concentration occurs around 1.5 hours after oral dosing, with a half-life of roughly 3.6 hours.[11][12] LAE-32's shorter reported duration may reflect faster receptor dissociation or differences in metabolism.[13]
Neuroscience[edit]
Neuroscience
Where it acts
Serotonergic psychedelics disrupt two brain systems. They reduce coordinated activity in the default mode network — the regions responsible for the narrative sense of self — producing ego dissolution and identity alteration. They also disrupt the thalamic filter that normally limits sensory input, generating perceptual distortion and geometric hallucinations.[2]
Why it matters
One influential framework proposes that psychedelics loosen the brain's reliance on prior expectations, allowing raw sensory signals greater influence over consciousness.[14] LSD also increases functional connectivity between normally separate brain regions.[10] Whether LAE-32 shares these properties depends on its serotonin receptor activity, which has not been measured.
LAE-32's shorter duration and more sedating character raise unanswered questions. The sedation and apathy described in historical accounts[1] might reflect a different balance of receptor activity compared to LSD, or faster receptor dissociation — but no data exist to test either possibility. Whether the compound promotes neuroplasticity remains entirely open.
inferred This entire section is based on class inference. No direct neuroscience data exist for LAE-32.
Subjective Effects[edit]
Subjective Effects
LAE-32 produces a psychedelic experience defined by its inward, sedating character. The visual and cognitive shifts of classical psychedelics are present, but they arrive in a quieter, heavier register — with apathy and motivation suppression in the foreground rather than the alert, analytical stimulation typical of related compounds.[1]
Within the lysergamide family, LAE-32 sits closer to ergine (LSA) than to LSD.[1] Where LSD sharpens attention and generates elaborate visual content, LAE-32 is dreamier and more physically weighted — a profile described in historical accounts as closer to a sedating natural alkaloid than to a synthetic psychedelic.
The compound emerged from Albert Hofmann's systematic exploration of lysergic acid derivatives at Sandoz Laboratories in the 1950s — the same programme that produced LSD. A handful of Italian clinical reports between 1955 and 1959 constitute the entire primary literature;[3][4][1][5] no further investigation followed. It has never appeared on contemporary research chemical markets and remains an obscure historical footnote within the Sandoz lysergamide series.
Subjective effects include geometric visual patterns, identity alteration, personal insight, and motivation suppression. The experience is reported as dreamier, heavier, and more sedating than LSD — closer in character to ergine (LSA) than to the bright analytical stimulation of its diethyl parent.[1] Anxiety, apathy, and bodily heaviness are characteristic unsought effects.
LAE-32 produces no physical dependence, and ergoline psychedelics as a class demonstrate high physiological safety with therapeutic indices exceeding 1000 in animal models.[2] The primary risk is psychological — acute panic, transient psychosis, or destabilisation in predisposed individuals — amplified by dose and uncontrolled setting. The evidence base is exceptionally sparse: all primary data are in untranslated Italian, no modern pharmacological study has been conducted, and every quantitative parameter is a class-level inference.
History[edit]
History
Discovery
LAE-32 was synthesized at Sandoz Laboratories in Basel as part of Albert Hofmann's systematic investigation of lysergic acid amide derivatives — the same research programme that produced LSD. The designation "LAE-32" follows the Sandoz internal numbering system (Lysergsäure-Äthylamid, compound 32). The earliest indexed clinical report appeared in 1955, when Tonini and Montanari described its psychological effects in human subjects.[3]
Clinical research
A small body of Italian-language clinical literature followed. Callieri and Ravetta (1957) documented psychopathological experiences during combined LAE-32 and LSD-25 administration.[4] Giberti and Gregoretti (1958) conducted the most informative study — a comparative investigation of LAE-32 versus LSD-25 in neurotic patients.[1] Soriani and Favale (1959) published the sole preclinical study, examining LAE-32's interaction with chronic serotonin treatment in mice.[5] All four publications appeared in Italian journals without digitized abstracts, contributing to the compound's near-total obscurity.
Modern status
No further investigation of LAE-32 has been published since 1959. The compound has not appeared on contemporary research chemical markets or been the subject of any registered clinical trial. It remains a historical curiosity, overshadowed by LSD and by novel lysergamides such as 1P-LSD, ALD-52, and ETH-LAD that have gained traction in both research and grey-market contexts.
The name "LAE-32" derives from the German Lysergsäure-Äthylamid (lysergic acid ethylamide), following Sandoz's internal compound numbering convention. The compound has no street names and no cultural presence outside specialist pharmacological literature. Multiple secondary sources claim LAE-32 was tested within the CIA's Project MKULTRA programme, but this has not been confirmed from primary declassified documents.citation needed
Chemistry[edit]
Chemistry
Structural class
LAE-32 belongs to the ergoline and lysergamide chemical classes, sharing the tetracyclic ergoline scaffold common to all lysergic acid derivatives. It is the N-monoethylamide of d-lysergic acid — the simplest N-alkyl lysergamide in the Sandoz series. The compound differs from LSD (N,N-diethyllysergamide) by the replacement of one ethyl group on the amide nitrogen with hydrogen, reducing steric bulk at the pharmacophore and lowering 5-HT₂A binding affinity.[6]
| Molecular formula | C₁₈H₂₁N₃O |
| Molecular weight | 295.4 g/mol |
Structure-activity relationships
The orientation and geometry of amide substituents in lysergamides are critical determinants of receptor binding. Nichols et al. (2002) demonstrated that the diethylamide moiety of LSD achieves optimal hydrophobic contact with 5-HT₂A; the loss of one ethyl group in LAE-32 diminishes these interactions, accounting for the 10–20-fold potency reduction.[6] Halberstadt et al. (2019) confirmed that N-monoalkyl lysergamides retain psychedelic activity, characterising the closely related compound ECPLA.[7]
The ergoline scaffold comprises four fused rings: an indole system (rings A and B), a cyclohexane (ring C), and a piperidine (ring D). The amide linkage at position 9 bears a single N-ethyl substituent, placing LAE-32 structurally between ergine (LSA, unsubstituted amide) and LSD (diethyl amide).[8]
Stereochemistry
LAE-32 possesses two chirality centres at positions 6a and 9. The pharmacologically active form is the (6aR,9R) stereoisomer, corresponding to the d-lysergic acid configuration.[8] Monte et al. (1995) confirmed that this stereoconfiguration is essential for activity at serotonin receptors across the lysergic acid amide series; the corresponding iso-lysergic acid configuration is pharmacologically inactive or substantially weaker.[9]
Physical properties
No published data on melting point, solubility, or stability exist for LAE-32. By analogy with LSD and other ergoline lysergamides, the compound is expected to be sensitive to light, heat, and oxidation.citation needed
Pharmacology[edit]
Pharmacology
Mechanism of action
No substance-specific receptor binding or functional assay has been published for LAE-32. All pharmacological characterisation is inferred from its structural relationship to LSD and the broader lysergamide class.
The psychedelic effects of ergoline lysergamides arise primarily from partial agonism at the serotonin 5-HT₂A receptor, particularly on layer V pyramidal neurons in the cortex. Activation of these receptors increases glutamate release, likely via thalamocortical afferents, producing the perceptual and cognitive disruption characteristic of classical psychedelics.[2]
Beyond 5-HT₂A, LSD-class ergolines interact broadly with monoamine systems. De Gregorio et al. (2016) documented activity at 5-HT₁A, dopamine D₂, and Trace Amine-Associated Receptor 1 (TAAR₁).[10] Ray (2010) confirmed that lysergamide ergolines interact with at least 51 receptor sites.[11] LAE-32 is expected to share this broad pharmacological profile, though with reduced affinity at most targets due to its monoethyl substitution.
The 10–20-fold potency reduction relative to LSD (active dose 500–1500 µg versus 25–150 µg) reflects diminished hydrophobic interactions at 5-HT₂A caused by the loss of one ethyl group.[6][1] The correct stereoconfiguration — (6aR,9R) — is required for activity at both 5-HT₂A and 5-HT₁A across the lysergamide series.[9]
inferred All pharmacological designations for LAE-32 are structural inferences from the lysergamide class. No substance-specific binding or functional data exist.
Pharmacokinetics
No human pharmacokinetic data have been published for LAE-32. Time to peak effect, plasma half-life, oral bioavailability, and metabolic pathways are unknown.
The closest available reference is oral LSD, for which Dolder et al. (2015) reported a time to peak plasma concentration of approximately 1.5 hours and a half-life of approximately 3.6 hours at 200 µg.[12] Holze et al. (2024) confirmed and extended these parameters.[13] Direct extrapolation to LAE-32 is not validated.
LAE-32's shorter reported duration (4–10 hours versus 8–12 hours for LSD) may reflect faster receptor dissociation or differences in metabolic clearance, but no data distinguish among these possibilities. By structural analogy with LSD metabolism, N-deethylation of the monoethyl group would produce lysergic acid amide (ergine/LSA); hydroxylation products are also expected.[14]
Neuroscience[edit]
Neuroscience
No neuroimaging, electrophysiological, or neuroplasticity studies have been conducted with LAE-32. All neural mechanisms described below are inferred from LSD and the classical psychedelic class.
Where it acts
Serotonergic psychedelics disrupt two brain systems that shape ordinary waking consciousness. They reduce the coordinated activity of the default mode network — the set of regions supporting self-referential thought and the narrative sense of self — producing ego dissolution and identity alteration. Simultaneously, 5-HT₂A activation on cortical neurons disrupts the thalamic filter that normally gates sensory input,[2] generating perceptual distortion and geometric hallucinations. LSD additionally increases entropy in cortical activity and promotes functional connectivity between normally segregated brain regions,[10] a pattern correlated with feelings of unity.
Why it matters
The REBUS framework (Relaxed Beliefs Under Psychedelics) proposes that psychedelics loosen the brain's reliance on prior expectations, allowing raw sensory signals greater influence over conscious experience.[15] This accounts for the perceptual, cognitive, and self-referential effects of the class. Classical psychedelics also promote structural neuroplasticity via BDNF-TrkB-mTOR signalling, though whether LAE-32 shares this property depends on its 5-HT₂A efficacy, which has not been measured.
LAE-32's shorter duration and more sedating character raise several unanswered questions. The sedation and apathy reported in historical accounts[1] could arise from a different balance of 5-HT₂A versus 5-HT₁A activity, or from faster receptor dissociation — but no kinetic or binding data exist to test either hypothesis.
inferred This entire section is based on class inference. No direct neuroscience data exist for LAE-32.
Subjective Effects[edit]
Subjective Effects
LAE-32 produces a serotonergic psychedelic experience defined by its sedating, inward-turning character. Historical clinical accounts emphasise apathy, motivation suppression, and a quiet cognitive tone alongside standard psychedelic phenomena — perceptual shifts, identity alteration, and personal insight.[1] Set, setting, and psychological preparation exert the same decisive influence on experience quality as with all serotonin 2A receptor agonists; the sedating baseline does not eliminate the potential for intense or destabilising experiences at higher doses.
Within the lysergamide series, LAE-32 sits closer to ergine (LSA) than to LSD — lower potency, shorter duration, and a heavier somatic quality. Where LSD is bright, analytically stimulating, and visually elaborate, LAE-32 is described as dreamier and more physically weighted. This characterisation rests on secondary citations of 1950s Italian clinical reports rather than controlled comparison data.
Effect Grid
Full psychedelic effects emerge at common doses (500-1500 µg oral). Perceptual distortion includes color enhancement, visual drifting, and mild geometry. Identity alteration and personal insight are characteristic at this range. The experience is distinctly sedating and introspective — motivation suppression and apathy are prominent features that distinguish LAE-32 from the stimulating character of LSD.
Bodily heaviness, body high, vasoconstriction, and nausea are typical physical accompaniments. Muscle tension and pupil dilation are expected. Anxiety is possible, particularly in unfamiliar settings or without adequate psychological preparation.
Duration spans 4-10 hours. Emotional enhancement, thought connectivity, and time alteration contribute to a dreamy, inward-directed experience. Set and setting remain decisive in shaping the qualitative character.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual breathing · Visual drifting · Auditory enhancement · Brightness alteration · Environmental patterning · Light sensitivity · Tracers · Ganzfeld effect · After-images · Auditory distortion · Depth perception distortion · Holotropic state · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Sound sensitivity · Spatial disorientation · Symmetrical texture repetition · Touch enhancement · Visual diffraction · Visual haze / noise · Visual melting · Visual morphing · Auditory misinterpretation · Dreaming enhancement · Peripheral misidentification · Synesthesia · Vestibular distortion · Visual acuity enhancement · Visual processing acceleration · Tinnitus · Visual magnification · Olfactory enhancement · Flashbacks · Taste enhancement · Internal hallucinations · Object transformations · Object activation · Visual recursion · External hallucinations · Auditory hallucinations · Environmental orbism / cubism · Perspective hallucinations · Visual flipping · Visual scenery slicing · Persisting hallucinations
Environmental patterning · Light sensitivity · Tracers · Ganzfeld effect · After-images · Auditory distortion · Depth perception distortion · Holotropic state · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Sound sensitivity · Spatial disorientation · Symmetrical texture repetition · Touch enhancement · Visual diffraction · Visual haze / noise · Visual melting · Visual morphing · Auditory misinterpretation · Dreaming enhancement · Peripheral misidentification · Synesthesia · Vestibular distortion · Visual acuity enhancement · Visual processing acceleration · Tinnitus · Visual magnification · Olfactory enhancement · Flashbacks · Taste enhancement · Internal hallucinations · Object transformations · Object activation · Visual recursion · External hallucinations · Auditory hallucinations · Environmental orbism / cubism · Perspective hallucinations · Visual flipping · Visual scenery slicing · Persisting hallucinations
Body scan awareness · Body high · Insomnia · Nausea · Spontaneous body sensations · Appetite suppression · Body schema distortion · Dizziness · Heart rate perception changes · Laughter fits · Physical fatigue · Restlessness · Tingling / electric sensations · Vibrations / buzzing · Sedation · Bodily heaviness · Bodily lightness · Dry mouth · Excessive sweating · Headache · Motor control impairment · Muscle tension · Tactile euphoria · Trembling · Abnormal heartbeat · Bodily pressures · Breathing alteration · Dehydration sensation · Involuntary body movements · Nystagmus (eye wobbles) · Sexual arousal enhancement · Vomiting · Yawning · Bodily dissociation · Tactile hallucination
Nausea · Spontaneous body sensations · Appetite suppression · Body schema distortion · Dizziness · Heart rate perception changes · Laughter fits · Physical fatigue · Restlessness · Tingling / electric sensations · Vibrations / buzzing · Sedation · Bodily heaviness · Bodily lightness · Dry mouth · Excessive sweating · Headache · Muscle tension · Tactile euphoria · Trembling · Abnormal heartbeat · Bodily pressures · Breathing alteration · Dehydration sensation · Involuntary body movements · Nystagmus (eye wobbles) · Sexual arousal enhancement · Vomiting · Yawning · Bodily dissociation · Tactile hallucination
Immersion enhancement · Introspection enhancement · Novelty enhancement · Openness enhancement · Pattern recognition enhancement · Thought connectivity · Cognitive euphoria · Multiple thought streams · Thought acceleration · Creativity enhancement · Motivation suppression · Analysis enhancement · Cognitive impairment · Humor enhancement · Increased nature relatedness · Thought loops · Information processing enhancement · Cognitive fatigue · Confusion · Focus suppression · Information processing suppression · Memory fragmentation · Synchronicity · Thought disorganization · Focus enhancement · Language enhancement · Cognitive dysphoria · Language suppression · Memory replays · Memory suppression · Motivation enhancement
Pattern recognition enhancement · Thought connectivity · Cognitive euphoria · Multiple thought streams · Thought acceleration · Creativity enhancement · Motivation suppression · Analysis enhancement · Cognitive impairment · Humor enhancement · Increased nature relatedness · Thought loops · Information processing enhancement · Cognitive fatigue · Confusion · Focus suppression · Information processing suppression · Memory fragmentation · Synchronicity · Thought disorganization · Focus enhancement · Language enhancement · Cognitive dysphoria · Language suppression · Memory replays · Memory suppression · Motivation enhancement
Anxiety · Catharsis · Empathy enhancement · Anxiety suppression · Dysphoria · Irritability
Dysphoria · Irritability
Trust enhancement · Sociability enhancement · Disinhibition · Communication enhancement · Flow state · Automaticity · Communication suppression · Compulsive behavior reduction · Ego inflation · Sociability suppression · Social disconnection · Boundary dissolution · Identity alteration · Ego dissolution · Cognitive disconnection · Telepathic feelings
Flow state · Automaticity · Communication suppression · Compulsive behavior reduction · Ego inflation · Sociability suppression · Social disconnection · Boundary dissolution · Identity alteration · Ego dissolution · Cognitive disconnection · Telepathic feelings
Time cessation
Transpersonal visions · Transpersonal memory access · Cessation · Death-rebirth sequence · Entity contact · Voidness · Near-death experience
Entity contact · Voidness · Near-death experience
Sustained attention (vicara) · Lucidity enhancement · Cognitive dissonance · Mindfulness enhancement · One-pointedness (ekaggata) · Recursive awareness
One-pointedness (ekaggata) · Recursive awareness
Timeline
First perceptible effects emerge — mild body awareness shifts and subtle changes in sensory texture. Effects are sub-threshold and easily dismissed.
Progressive perceptual alteration and increasing bodily heaviness. Sedation begins to assert itself as a defining feature. Mild nausea possible.
Full psychedelic effects — maximal perceptual distortion, identity alteration, and introspection. Sedation and motivation suppression are prominent. Anxiety possible.
Gradual reduction in perceptual and cognitive effects. Sedation and bodily heaviness may persist longer than visual phenomena. Thought processes begin to normalize.
Residual mood effects, mild perceptual sensitivity, and physical fatigue. Cognitive clarity returns but subtle emotional shifts may linger.
⚠ Do not drive or operate heavy machinery for at least 12 hours after ingestion, as residual cognitive and perceptual effects may persist.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 6 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Safety
Toxicity
No toxicity data exist for LAE-32. Ergolines as a class demonstrate very high physiological safety at psychoactive doses — among the least toxic drugs known, with safety margins exceeding 1000 in animal testing.[2] No human fatalities have been attributed to the compound.
Ergoline compounds may theoretically damage heart valves with prolonged repeated use — as documented for ergotamine and methysergide — but this pertains to chronic dosing regimens rather than infrequent psychedelic use.safety citation needed Whether LAE-32 carries this risk is unknown.
Psychological risks
- Acute anxiety and panic: anxiety, paranoia, and overwhelming perceptual distortion can occur at any dose, increasing with dose and in uncontrolled settings. Historical reports of LAE-32 specifically note anxiety as an observed effect.[1]
- Transient psychosis: Delusional thinking, disorganized thought, and loss of reality contact are a recognized risk of all serotonin-activating psychedelics. Risk is elevated in individuals with a personal or family history of psychotic disorders.
- Persistent visual disturbances (HPPD): Ongoing visual disturbances after psychedelic use have been documented for classical psychedelics. No LAE-32-specific cases exist, but the risk is presumed for all drugs of this class.
- Psychological destabilisation: Intense experiences can trigger or worsen anxiety disorders, depression, or identity disturbance, particularly without adequate support.
Tolerance and dependence
LAE-32 does not produce physical dependence or withdrawal.[2] Rapid tolerance builds within 3–4 days of repeated use through serotonin downregulation, then clears over a similar period.[15]
Cross-tolerance with other classical psychedelics — including LSD, psilocybin, and mescaline — is expected.[15] Compulsive redosing is not expected; psychedelics do not activate the brain's reward circuitry in a way associated with addiction.
Drug interactions
Serotonergic compounds: Combining LAE-32 with other serotonergic drugs creates additive serotonin stimulation. Tramadol[16] and MAOIs are classified as dangerous: they prevent serotonin breakdown or block its reuptake — combined with LAE-32's direct receptor activation, this can produce dangerous overheating, muscle rigidity, and altered consciousness.safety citation needed SSRIs, SNRIs, and serotonin releasers carry analogous risk.
- Cannabis: Interaction severity is uncharacterized. Cannabis can amplify both positive and negative psychological effects.
- Cocaine: Interaction severity is uncharacterized. Both may increase heart rate and blood pressure simultaneously.
- Lithium: Combining lithium with serotonergic psychedelics has been associated with seizures.citation needed
Contraindications
No LAE-32-specific contraindication data exist. The following are inferred from the serotonin 2A receptor agonist and ergoline classes.
Absolute contraindications:
- Personal history of psychotic disorders (schizophrenia, schizoaffective disorder)
- Current MAOI use — risk of severe serotonin syndrome
- Current lithium use — risk of seizurescitation needed
Relative contraindications:
- Family history of psychotic disorders
- Bipolar disorder with psychotic features
- Severe cardiovascular disease
- Pregnancy — ergoline compounds stimulate uterine contractions as a classcitation needed
- Current SSRI/SNRI use — potential for serotonergic potentiation
inferred All contraindications are class-level inferences. No LAE-32-specific contraindication data exist.
Harm Reduction[edit]
Forms & Identification
LAE-32 is not available on contemporary research chemical markets. No verified samples have been documented in modern drug checking programmes. Any material claimed to be LAE-32 should be treated with extreme scepticism regarding identity and purity.
Because LAE-32 is a lysergamide active in the microgram range, dosing precision matters. Small measurement errors produce large differences in effect intensity. Standard reagent testing (Ehrlich/Hofmann) detects the presence of an indole but cannot distinguish LAE-32 from LSD, ergine, or other lysergamides. Confirming identity requires laboratory-grade analysis such as GC-MS.
Guidelines
- Test any material with Ehrlich reagent at minimum; pursue laboratory analysis if possible
- Start at the lowest reported active dose and wait the full expected onset period before considering redosing
- Choose a safe, comfortable, private environment with a trusted sober companion present
- Clear the schedule for the full reported duration plus several hours of recovery time
- Eat lightly beforehand; stay hydrated but avoid alcohol
- Have no driving or operating-machinery obligations for at least 12 hours
- Keep a phone accessible in case emergency services are needed
Set & Setting
As with all classical psychedelics, the psychological environment shapes the experience as powerfully as the dose. A calm, familiar physical space with trusted company reduces the probability of anxiety-driven escalation.
Historical accounts emphasise LAE-32's sedating character, but this does not make high-dose experiences inherently safe. A quieter cognitive tone can shift to confusion or distress without warning. First experiences should occur at the lower end of the reported dose range, with no obligations for the full duration. An experienced, sober companion is strongly recommended.
Aftercare & integration. The days following a psychedelic experience can bring emotional sensitivity, unusual thought patterns, and a lingering sense of unreality. These are normal and typically resolve within a few days. Journaling, quiet reflection, and conversation with trusted individuals can help process the experience.
If distressing thoughts, persistent anxiety, or visual disturbances continue beyond a week, seek professional support from a therapist experienced with psychedelic experiences. Integration circles and peer support communities can also provide context and reassurance.
Recovery & Support
Classical psychedelics carry minimal physical dependence risk, but psychological reliance on altered states — using psychedelic experiences to avoid addressing life problems — can develop. If psychedelic use is becoming a pattern of avoidance rather than exploration, professional support is warranted.
Resources include the Fireside Project (psychedelic peer support hotline), MAPS integration therapist directory, and local mental health services. For broader substance use concerns, SAMHSA's National Helpline (1-800-662-4357) provides free referrals.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognising an emergency: Most difficult psychedelic experiences are frightening but not medically dangerous. Signs that require immediate help include: self-harm behaviour or stated intent, complete loss of contact with reality persisting beyond reassurance, seizure activity, or severe overheating.
Immediate steps:
- Move the person to a quiet, low-stimulation environment
- Speak calmly and reassuringly — remind them of who they are, where they are, and that the effects are temporary
- Do not restrain them unless they are in immediate physical danger
- If symptoms escalate or the person becomes unresponsive, call emergency services
What to tell the dispatcher: State that the person has taken a psychedelic substance, the approximate amount and time of ingestion, and the current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
Legal Status
LAE-32 is not specifically scheduled as a controlled substance in most jurisdictions — its legal status depends on structural analog provisions and blanket psychoactive substance bans rather than explicit listing.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not specifically scheduled | Not listed in the DEA Controlled Substances Act. As a structural and pharmacological analogue of LSD (Schedule I), the Federal Analogue Act (21 U.S.C. § 813) may apply if intended for human consumption. No DEA ruling or court case addressing LAE-32 has been identified. |
| United Kingdom | Controlled under Psychoactive Substances Act 2016 | Not added to Schedule 1 of the Misuse of Drugs Act 1971 by the 2015 amendment, which listed ALD-52, AL-LAD, ETH-LAD, PRO-LAD, and LSZ.[17] Covered by the blanket ban under the Psychoactive Substances Act 2016 — illegal to supply or produce, though simple possession is not a criminal offence under that Act. |
| Canada | Not specifically scheduled | Not listed in the Controlled Drugs and Substances Act schedules as of 2025.citation needed |
| Australia | Not specifically listed nationally | Not scheduled by the TGA. State-level blanket bans on novel psychoactive substances (QLD, NSW, SA, VIC) would capture LAE-32 as a psychoactive compound. |
| European Union | No specific EU-level scheduling | Member state legislation varies. Blanket NPS laws (Germany NPSG, Poland NPS Act, and others) may apply. No EMCDDA risk assessment for LAE-32 has been conducted. |
Analogue considerations
LAE-32 is the direct structural precursor of LSD, differing by one ethyl group on the amide nitrogen. In jurisdictions with analogue acts or structural similarity provisions — including the United States and New Zealand — this creates legal ambiguity. Prosecution under the US Federal Analogue Act requires demonstrating substantial chemical and pharmacological similarity to a Schedule I substance, criteria LAE-32 plausibly meets.
Legal status changes frequently and varies by jurisdiction. This information is not legal advice. Verify current scheduling through official regulatory sources before any involvement with this compound.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 6 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Safety
Toxicity
No controlled toxicity data exist for LAE-32. No lethal dose has been determined in any species, and no human fatalities have been attributed to the compound.
Ergoline psychedelics as a class demonstrate high physiological safety at psychoactive doses. Nichols (2004) noted that classical psychedelics are among the least toxic drugs known, with therapeutic indices exceeding 1000 in animal models.[2] This safety profile is plausible for LAE-32 but has not been confirmed by substance-specific data.safety citation needed
Chronic toxicity has not been studied.safety citation needed Ergoline compounds carry a theoretical risk of heart valve damage through serotonin₂B receptor activity with repeated dosing (as documented for ergotamine and methysergide), but this pertains to chronic dosing regimens rather than infrequent psychedelic use. Whether LAE-32 has meaningful 5-HT₂B activity is unknown.
As an ergoline, LAE-32 is expected to produce mild stimulant-like physical effects — pupil dilation, modest increases in heart rate and blood pressure. No specific cardiovascular safety data exist.
Psychological risks
- Acute anxiety and panic: anxiety, paranoia, and overwhelming perceptual distortion can occur at any dose, with risk increasing at higher doses and in uncontrolled settings. Historical reports of LAE-32 specifically note anxiety as an observed effect.[1]
- Transient psychosis: Acute psychotic episodes — delusions, disorganised thought, loss of reality contact — are a recognised risk of all serotonin 2A receptor agonists. Risk is elevated in individuals with personal or family history of psychotic disorders.
- Persistent visual disturbances (HPPD): Ongoing visual disturbances after psychedelic use have been documented for LSD and other classical psychedelics. No LAE-32-specific cases exist, but the risk is presumed for all 5-HT₂A agonists.
- Psychological destabilisation: Intense psychedelic experiences can trigger or worsen anxiety disorders, depression, or identity disturbance, particularly without adequate psychological support.
Tolerance and dependence
Ergoline psychedelics do not produce physical dependence or withdrawal. Nichols (2004) stated that psychedelics as a class "do not produce dependence or addiction".[2]
Rapid tolerance develops with repeated use through 5-HT₂A downregulation. De la Fuente Revenga et al. (2022) confirmed this mechanism and demonstrated cross-tolerance between DOI and LSD in animal models.[16] Tolerance builds within 3–4 days of repeated administration and resolves over a similar period.
Cross-tolerance with other classical psychedelics — including LSD, psilocybin, and mescaline — is expected.[16] Compulsive redosing is not expected; psychedelics do not activate reward circuitry in a manner associated with reinforcement.
Drug interactions
Serotonergic compounds: The primary interaction concern is serotonin syndrome when combined with other serotonergic agents. Tramadol — a weak opioid that also blocks serotonin reuptake[17] — carries a dangerous interaction classification. The combination of LAE-32's direct serotonin receptor activation with tramadol's reuptake inhibitor creates additive serotonergic stimulation that can produce dangerous overheating, muscle rigidity, and altered consciousness.safety citation needed
Other serotonergic agents carrying analogous risk include SSRIs, SNRIs, MAOIs, and serotonin releasers. MAOIs are of particular concern: they can dramatically potentiate serotonergic psychedelics by preventing serotonin breakdown, and this interaction is well-documented across the tryptamine and ergoline classes.
Cannabis: Interaction severity is uncharacterised. Cannabis can subjectively intensify psychedelic experiences, amplifying both positive and negative psychological effects.
Cocaine: Interaction severity is uncharacterised. Both compounds may increase heart rate and blood pressure through complementary mechanisms, raising theoretical cardiovascular risk.
Lithium: A known dangerous interaction across the psychedelic class. Lithium combined with serotonergic psychedelics has been associated with seizures.citation needed
Contraindications
No LAE-32-specific contraindication data exist. The following are inferred from the 5-HT₂A agonist and ergoline classes:
Absolute contraindications:
- Personal history of psychotic disorders (schizophrenia, schizoaffective disorder)
- Current MAOI use — risk of severe serotonin syndrome and uncontrolled potentiation
- Current lithium use — risk of seizures and serotonin syndromecitation needed
Relative contraindications:
- Family history of psychotic disorders
- Bipolar disorder with psychotic features
- Severe cardiovascular disease
- Pregnancy — ergoline compounds are contraindicated in pregnancy as a class due to uterine-stimulating propertiescitation needed
- Current SSRI/SNRI use — potential for serotonergic potentiation and unpredictable effect modification
inferred All contraindications are class-level inferences. No LAE-32-specific contraindication data exist.
Harm Reduction[edit]
Forms & Identification
LAE-32 is not available on contemporary research chemical markets, and no verified samples have been documented in modern drug checking programmes. Any material claimed to be LAE-32 should be treated with extreme scepticism regarding identity and purity.
Because LAE-32 is a lysergamide active in the microgram range, dosing precision is critical — small errors in measurement translate to large differences in effect intensity. Standard reagent testing (Ehrlich/Hofmann) would indicate the presence of an indole but cannot distinguish LAE-32 from LSD, ergine, or other lysergamides. Confirming identity would require laboratory-grade analysis (GC-MS or equivalent).
Guidelines
- Test any material with Ehrlich reagent at minimum; pursue laboratory analysis if possible
- Start at the lowest reported active dose and wait the full expected onset period before considering redosing
- Choose a safe, comfortable, private environment with a trusted sober companion present
- Clear the schedule for the full reported duration plus several hours of recovery time
- Eat lightly beforehand; stay hydrated but avoid alcohol
- Have no driving or operating-machinery obligations for at least 12 hours
- Keep a phone accessible in case emergency services are needed
Set & Setting
As with all classical psychedelics, the psychological environment shapes the experience as powerfully as the dose. A calm, familiar physical space with trusted company reduces the probability of anxiety-driven escalation. Historical accounts emphasise LAE-32's sedating and introspective character, but this does not make high-dose experiences inherently safe — the quieter cognitive tone can shift to confusion or distress without warning.
First experiences should occur at the lower end of the reported dose range, with no obligations for the duration. An experienced, sober companion ("trip sitter") who can provide reassurance and practical help is strongly recommended.
Aftercare & integration. The days following a psychedelic experience can bring emotional sensitivity, unusual thought patterns, and a lingering sense of unreality. These are normal and typically resolve within a few days. Journaling, quiet reflection, and conversation with trusted individuals can help process the experience.
If distressing thoughts, persistent anxiety, or visual disturbances continue beyond a week, seek professional support from a therapist experienced with psychedelic experiences. Integration circles and peer support communities can also provide context and reassurance.
Recovery & Support
Classical psychedelics carry minimal physical dependence risk, but psychological reliance on altered states — using psychedelic experiences to avoid addressing life problems — can develop. If psychedelic use is becoming a pattern of avoidance rather than exploration, professional support is warranted.
Resources include the Fireside Project (psychedelic peer support hotline), MAPS integration therapist directory, and local mental health services. For broader substance use concerns, SAMHSA's National Helpline (1-800-662-4357) provides free referrals.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognising an emergency: Most difficult psychedelic experiences are frightening but not medically dangerous. Signs that require immediate help include: self-harm behaviour or stated intent, complete loss of contact with reality persisting beyond reassurance, seizure activity, or severe overheating.
Immediate steps:
- Move the person to a quiet, low-stimulation environment
- Speak calmly and reassuringly — remind them of who they are, where they are, and that the effects are temporary
- Do not restrain them unless they are in immediate physical danger
- If symptoms escalate or the person becomes unresponsive, call emergency services
What to tell the dispatcher: State that the person has taken a psychedelic substance, the approximate amount and time of ingestion, and the current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
Legal Status
LAE-32 is not specifically scheduled as a controlled substance in most jurisdictions. Its legal status depends on structural analog provisions, blanket psychoactive substance bans, and national legislation rather than explicit listing. As of 2026, no jurisdiction has specifically named LAE-32 in a controlled substances schedule.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not specifically scheduled | Not listed in the DEA Controlled Substances Act. As a structural and pharmacological analogue of LSD (Schedule I), the Federal Analogue Act (21 U.S.C. § 813) may apply if intended for human consumption. No DEA ruling or court case addressing LAE-32 has been identified. |
| United Kingdom | Controlled under Psychoactive Substances Act 2016 | Not added to Schedule 1 of the Misuse of Drugs Act 1971 by the 2015 amendment, which listed ALD-52, AL-LAD, ETH-LAD, PRO-LAD, and LSZ.[18] Covered by the blanket ban under the Psychoactive Substances Act 2016 — illegal to supply or produce, though simple possession is not a criminal offence under that Act. |
| Canada | Not specifically scheduled | Not listed in the Controlled Drugs and Substances Act schedules as of 2025.citation needed |
| Australia | Not specifically listed nationally | Not scheduled by the TGA. State-level blanket bans on novel psychoactive substances (QLD, NSW, SA, VIC) would capture LAE-32 as a psychoactive compound. |
| European Union | No specific EU-level scheduling | Member state legislation varies. Blanket NPS laws (Germany NPSG, Poland NPS Act, and others) may apply. No EMCDDA risk assessment for LAE-32 has been conducted. |
Analogue considerations
LAE-32 is the direct structural precursor of LSD, differing by one ethyl group on the amide nitrogen. In jurisdictions with analogue acts or structural similarity provisions (United States, New Zealand, and others), this close relationship creates legal ambiguity. Prosecution under the US Federal Analogue Act requires demonstration that the substance is "substantially similar" in both chemical structure and pharmacological effect to a Schedule I substance — criteria LAE-32 plausibly meets.
Individuals should assume legal risk in any jurisdiction with analogue legislation and verify current scheduling status through official regulatory sources before any involvement with this compound.
Frequently asked questions
How long does LAE-32 last?
Total duration by route of administration — Oral: 4 – 10 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for LAE-32?
Psychedex publishes a dosage table for LAE-32 on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with LAE-32?
The highest-severity documented interactions for LAE-32: MAOIs (Lethal), Dopamine agonists (Dangerous), GHB, Baclofen (Dangerous), GHB, GBL (Dangerous), Ibogaine (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is LAE-32 addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for LAE-32: tolerance builds rapid; full reset takes 6 days; cross-tolerance develops with LSD, psilocybin, mescaline, DMT. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2]
- [3] ^abTonini G, Montanari C (1955) Psychological effects of lysergic acid monoethylamide (LAE 32) — Giornale di psichiatria e di neuropatologia PMID:13251531
- [4] ^abCallieri B, Ravetta M (1957) Psychopathological experiences with the combined action of lysergic acid mono- and diethylamide (LAE-32, LSD-25) — Rivista sperimentale di freniatria e medicina legale delle alienazioni mentali PMID:13466954
- [5] ^abSoriani S, Favale E (1959) Protective action of lysergic acid ethylamide (LAE-32) on behavior changes and histological lesions of the CNS induced in mice by chronic 5-hydroxytryptamine treatment — Sistema nervoso PMID:13659105
- [6]
references
- [1]
- [2]
- [3] ^abTonini G, Montanari C (1955) Psychological effects of lysergic acid monoethylamide (LAE 32) — Giornale di psichiatria e di neuropatologia PMID:13251531
- [4] ^abCallieri B, Ravetta M (1957) Psychopathological experiences with the combined action of lysergic acid mono- and diethylamide (LAE-32, LSD-25) — Rivista sperimentale di freniatria e medicina legale delle alienazioni mentali PMID:13466954
- [5] ^abSoriani S, Favale E (1959) Protective action of lysergic acid ethylamide (LAE-32) on behavior changes and histological lesions of the CNS induced in mice by chronic 5-hydroxytryptamine treatment — Sistema nervoso PMID:13659105
- [6] ^abcNichols DE, Frescas S, Marona-Lewicka D, Kurrasch-Orbaugh DM (2002) Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD) — Journal of Medicinal Chemistry PMID:12213075